The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 14,524 | 10,738 |
| Stock-based compensation | 1,326 | 4,697 |
| Depreciation and amortization | 3,594 | 7,387 |
| Assets write-down | 0 | 34 |
| Inventory write-off and obsolescence | 809 | 1,620 |
| Provision for credit losses | 549 | 1,603 |
| Changes in value of life insurance policies | 1,017 | 834 |
| Deferred income taxes | 1,406 | 3,167 |
| Insurance recovery on property, plant and equipment | 5,273 | 1,557 |
| Other non-cash items | -286 | -566 |
| Accounts receivable | -3,102 | 3,717 |
| Inventories | -723 | 1,991 |
| Prepaid expenses and other current assets | -20 | 817 |
| Other assets | 242 | 109 |
| Accounts payable | -5,363 | 6,647 |
| Accrued expenses | -2,484 | -886 |
| Unearned revenues | -1,856 | -218 |
| Other liabilities | 1,210 | 587 |
| Net cash provided by operating activities | 8,502 | 20,583 |
| Capital expenditures - operations | 2,006 | 6,259 |
| Capital expenditures - rebuilding of aberdeen facility | 1,024 | 1,648 |
| Proceeds from insurance recovery - aberdeen facility | 5,273 | 4,678 |
| Patents and other intangibles | 2 | 0 |
| Acquisitions, net of cash acquired | 0 | 617 |
| Proceeds from sale of assets | 152 | 2,196 |
| Net proceeds on life insurance policies | 0 | -778 |
| Net cash provided by (used in) investing activities | 2,393 | -872 |
| Repayment of long-term debt | 20,000 | 27,000 |
| Proceeds from long-term debt | 11,000 | 25,000 |
| Debt issuance costs | 1,706 | - |
| Dividends paid | 465 | 938 |
| Repurchase of common stock | 5,009 | 4,761 |
| Equity related transaction costs | 0 | 0 |
| Other financing activity | -274 | 19 |
| Net cash used in financing activities | -16,454 | -7,680 |
| Net change in cash and cash equivalents | -5,559 | 12,031 |
| Cash and cash equivalents at beginning of period | 19,157 | - |
| Cash and cash equivalents at end of period | 25,629 | - |
Core Laboratories Inc. DE (CLB)
Core Laboratories Inc. DE (CLB)